PATIENT-REPORTED OUTCOMES FROM PHASE 3 BARICITINIB RA-BEAM STUDY- LATIN AMERICAN SUBGROUP ANALYSIS

Author(s)

Papadimitropoulos M1, Morales Ld2, Gonzaga JR3, Goncalves L4, Martinez-Osuna P5, Zhu B5, Gaich CL5, Garcia EG6
1Eli Lilly and Company, Canada and Assistant Professor, Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada, 2Instituto Reumatológico Strusberg, Córdoba, Argentina, 3Centro de Investigacion Clinica Especializad, Mexico City, Mexico, 4Eli Lilly and Company, São Paulo, Brazil, 5Eli Lilly and Company, Indianapolis, IN, USA, 6Eli Lilly and Company, Mexico City, Mexico

OBJECTIVES::  To evaluate effect of baricitinib (BARI) on patient-reported outcomes (PROs) in Latin American (LA)* patients with moderately to severely active rheumatoid arthritis (RA) with an inadequate response to methotrexate (MTX)

Conference/Value in Health Info

2017-09, ISPOR Latin America 2017, Sao Paulo, Brazil

Value in Health, Vol. 20, No. 9 (October 2017)

Code

PMS28

Topic

Patient-Centered Research

Topic Subcategory

Patient-reported Outcomes & Quality of Life Outcomes

Disease

Musculoskeletal Disorders

Explore Related HEOR by Topic

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×